Skip to content

Treatment of Hypertriglyceridemia with Fucus Vesiculosus vs Atorvastatin

A randomized controlled comparative pilot study to evaluate the efficacy of Fucus vesiculosus mother tincture in the treatment of Hypertriglyceridemia versus conventional Atorvastatin

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055898
Enrollment
60
Registered
2023-07-31
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E781- Pure hyperglyceridemia

Interventions

Intervention1: Fucus Vesiculosus Mother Tincture: Each dose of the medicine shall consist of 15 drops (0.75m1) mother tincture T.I.D. in half a cup of water for 12 weeks. The dosage has been taken fol

Sponsors

Central Council for Research in Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Men and women aged 20-65 years. 2.Known case of Hypothyroid, Type 2 Diabetics and Hypertension with control under medication. 3.Other systemic disorders under control with treatment. 4.Women surgically sterile, post-menopausal, are agreed to practice adequate contraception. 5.Written Informed consent from the patient. 6.Cases falling under Mild and Moderate [20]category of Serum Triglyceride levels as per the classification of Endocrine Society 2010

Exclusion criteria

Exclusion criteria: 1.Pregnancy, breastfeeding. 2.Cases with other uncontrolled systemic diseases like Hypothyroidism, Cardiovascular, Endocrinal diseases or systemic infections. 3.Low levels of Vitamin D. 4.Previous history of cardiovascular disease and cerebra stroke. 5.Suffering from known liver disorders. 6.Cases falling under Severe category of Serum Triglycerides levels as per the classification of Endocrine Society 2010.

Design outcomes

Primary

MeasureTime frame
Improvement assessment of the changes in Lipid profile at baseline, 8th week & 12th weekTimepoint: 12 weeks

Secondary

MeasureTime frame
BMI FFQ QoL by SF 36Timepoint: 12 weeks

Countries

India

Contacts

Public ContactDr Hima Bindu Ponnam

Central Council for Research in Homoeopathy

himabindu@ccrhindia.nic.in09490009899

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026